Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Omalizumab for the Treatment of Multiple Food Allergies.
Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Iqbal A, Olsson J, Ligueros-Saylan M, Uddin A, Calatroni A, Huckabee CM, Rogers NH, Yovetich N, Dantzer J, Mudd K, Wang J, Groetch M, Pyle D, Keet CA, Kulis M, Sindher SB, Long A, Scurlock AM, Lanser BJ, Lee T, Parrish C, Brown-Whitehorn T, Spergel AKR, Veri M, Hamrah SD, Brittain E, Poyser J, Wheatley LM, Chinthrajah RS. Wood RA, et al. Among authors: ligueros saylan m. N Engl J Med. 2024 Mar 7;390(10):889-899. doi: 10.1056/NEJMoa2312382. Epub 2024 Feb 25. N Engl J Med. 2024. PMID: 38407394 Clinical Trial.
Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH).
Wood RA, Chinthrajah RS, Rudman Spergel AK, Babineau DC, Sicherer SH, Kim EH, Shreffler WG, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Kulis M, Iqbal A, Kaufman D, Umetsu DT, Ligueros-Saylan M, Uddin A, Fogel RB, Lussier S, Mudd K, Poyser J, MacPhee M, Veri M, Davidson W, Hamrah S, Long A, Togias A; OUtMATCH study team. Wood RA, et al. Among authors: ligueros saylan m. J Allergy Clin Immunol Glob. 2022 Jul 21;1(4):225-232. doi: 10.1016/j.jacig.2022.05.006. eCollection 2022 Nov. J Allergy Clin Immunol Glob. 2022. PMID: 37779534 Free PMC article.
Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers.
Sangana R, Xu Y, Shah B, Tian X, Zack J, Shakeri-Nejad K, Kalluri S, Jones I, Ligueros-Saylan M, Taylor AF, Jain DK, Scosyrev E, Uddin A, Laurent N, Paganoni P. Sangana R, et al. Among authors: ligueros saylan m. Clin Pharmacol Drug Dev. 2024 Feb 22. doi: 10.1002/cpdd.1373. Online ahead of print. Clin Pharmacol Drug Dev. 2024. PMID: 38389387
Real-World Safety and Effectiveness of Omalizumab in Moderate to Severe Allergic Asthma Patients in China: A Post-Authorization Study.
Su N, Zhi L, Liu F, Wang Y, Zhang Q, Liu X, Wang X, Hao G, Zhang X, Hu Q, Ligueros-Saylan M, Uddin A, Yang J, Liang T, Ding L, Li R, Wang C. Su N, et al. Among authors: ligueros saylan m. J Asthma Allergy. 2023 Jun 19;16:625-636. doi: 10.2147/JAA.S406628. eCollection 2023. J Asthma Allergy. 2023. PMID: 37360967 Free PMC article.
Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria.
Yuan W, Hu S, Li M, Yang L, Liu L, Zheng M, Guo Z, Song Z, Zhang C, Diao Q, Xu J, Richard A, Patwardhan M, Lyu T, Uddin A, Fogel R, Ligueros-Saylan M, Zheng J. Yuan W, et al. Among authors: ligueros saylan m. Dermatol Ther. 2022 Apr;35(4):e15303. doi: 10.1111/dth.15303. Epub 2022 Jan 17. Dermatol Ther. 2022. PMID: 34984792 Free PMC article. Clinical Trial.
Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study.
Gevaert P, Saenz R, Corren J, Han JK, Mullol J, Lee SE, Ow RA, Zhao R, Howard M, Wong K, Islam L, Ligueros-Saylan M, Omachi TA, Bachert C. Gevaert P, et al. Among authors: ligueros saylan m. J Allergy Clin Immunol. 2022 Mar;149(3):957-965.e3. doi: 10.1016/j.jaci.2021.07.045. Epub 2021 Sep 14. J Allergy Clin Immunol. 2022. PMID: 34530020 Free article. Clinical Trial.
Reply.
Gevaert P, Corren J, Mullol J, Han J, Lee SE, Ligueros-Saylan M, Wong K, Omachi TA, Bachert C. Gevaert P, et al. Among authors: ligueros saylan m. J Allergy Clin Immunol. 2021 Jan;147(1):413-414. doi: 10.1016/j.jaci.2020.09.025. Epub 2020 Nov 5. J Allergy Clin Immunol. 2021. PMID: 33160643 No abstract available.
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, Kaufman D, Ligueros-Saylan M, Howard M, Zhu R, Owen R, Wong K, Islam L, Bachert C. Gevaert P, et al. Among authors: ligueros saylan m. J Allergy Clin Immunol. 2020 Sep;146(3):595-605. doi: 10.1016/j.jaci.2020.05.032. Epub 2020 Jun 7. J Allergy Clin Immunol. 2020. PMID: 32524991 Free article. Clinical Trial.
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
Schopohl J, Gu F, Rubens R, Van Gaal L, Bertherat J, Ligueros-Saylan M, Trovato A, Hughes G, Salgado LR, Boscaro M, Pivonello R; Pasireotide B2305 Study Group. Schopohl J, et al. Among authors: ligueros saylan m. Pituitary. 2015 Oct;18(5):604-12. doi: 10.1007/s11102-014-0618-1. Pituitary. 2015. PMID: 25537481 Free PMC article. Clinical Trial.
Effect of food on the oral bioavailability of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide fixed dose combination tablets in healthy subjects.
Sunkara G, Jiang X, Reynolds C, Serra D, Zhang Y, Ligueros-Saylan M, Ayalasomayajula S, Winter S, Jarugula V. Sunkara G, et al. Among authors: ligueros saylan m. Clin Pharmacol Drug Dev. 2014 Nov;3(6):487-92. doi: 10.1002/cpdd.131. Epub 2014 Jun 2. Clin Pharmacol Drug Dev. 2014. PMID: 27129123
42 results